Results 121 to 130 of about 7,761,818 (273)

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Complete list of 1009 drug–gene interactions identified through DrugBank analysis.

Complete list of 1009 drug–gene interactions identified through DrugBank analysis.
Aleksandra Panina (24375685), Robert Fredriksson (27811), Helgi B. Schiöth (7413461), Ayse Arzu Şakul (24375688), Ebrar Altınalan (24375682)   +4 more
core   +1 more source

Graph attention networks for predicting drug-gene association of glucocorticoid in oral squamous cell carcinoma: A comparison with GraphSAGE.

PLoS ONE
BackgroundThe present study evaluates the effectiveness of Graph Attention Networks (GAT) and GraphSAGE in predicting drug-gene interactions for glucocorticoids in oral squamous cell carcinoma, thereby aiding in developing better treatment strategies ...
Monal Yuwanati, Santhanamari Thiyagarajan, Kranti Kiran Reddy Ealla, Yash Jain, Pradeep Kumar Yadalam, Senthil Murugan Mullainathan, Anima Nanda, Samir Sahoo, Daniel Ejim Uti   +8 more
doaj   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Genetic insights into the shared molecular mechanisms of Crohn’s disease and breast cancer: a Mendelian randomization and deep learning approach

Discover Oncology
The objective of this study was to explore the potential genetic link between Crohn’s disease and breast cancer, with a focus on identifying druggable genes that may have therapeutic relevance.
Zhuang Zhuang Wang, Ju Lin Yang, Zong Yao Zhang, Pei Bin Wang   +3 more
doaj   +1 more source

Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology

Molecular Oncology, EarlyView.
This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic, Maria Concetta Vitale, Rita Siino, Emilia Di Giovanni, Carla Ferrante Bannera, Enrico Di Marco, Andrea Gottardo, Tancredi Didier Bazan Russo, Nadia Barraco, Alessandro Perez, Valerio Gristina, Antonio Galvano, Giuseppe Badalamenti, Antonio Russo, Viviana Bazan, Lorena Incorvaia   +15 more
wiley   +1 more source

Use of artemether-lumefantrine in the treatment of asymptomatic-malaria infection in HIV-positive and HIVnegative Nigerian adults. [PDF]

Malaria /HIV co-infection is a major challenge to public health in developing countries and yet potential drug-drug interactions between antimalarial and antiviral regimens have not been adequately investigated in people with both HIV and Plasmodium ...
Chijioke-Nwauche, IN
core   +1 more source

Partial FAK suppression promotes tumor growth, an effect reversed by macrophage p110δ PI3K inactivation

Molecular Oncology, EarlyView.
Partial inhibition of focal adhesion kinase (FAK) can paradoxically promote tumor growth, rather than simply producing a weaker antitumor effect than that observed with strong FAK suppression. In breast cancer and melanoma models, targeting p110δ PI3K, particularly in macrophages, counteracted these tumor‐promoting effects, highlighting the importance ...
Lydia Xenou, Niki Tzenaki, Anna Tsapara, Maria Tzardi, Evangelia A. Papakonstanti   +4 more
wiley   +1 more source

Integrated edge information and pathway topology for drug-disease associations

iScience
Summary: Drug repurposing is a promising approach to find new therapeutic indications for approved drugs. Many computational approaches have been proposed to prioritize candidate anticancer drugs by gene or pathway level.
Xianbin Li, Xiangzhen Zan, Tao Liu, Xiwei Dong, Haqi Zhang, Qizhang Li, Zhenshen Bao, Jie Lin   +7 more
doaj   +1 more source